Response to: Long-term trials of pregabalin and duloxetine for fibromyalgia symptoms: How study designs can affect placebo factors

Pain

Volumn 139, Issue 2, 2008, Pages 477-479

  Moore, R A ^a   Derry, S ^a   McQuay, H J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PREGABALIN;

BACKACHE; CLINICAL PRACTICE; CLINICAL TRIAL; CONCENTRATION LOSS; DIARRHEA; DROWSINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; EVIDENCE BASED PRACTICE; FATIGUE; FIBROMYALGIA; HEADACHE; HUMAN; IRRITABILITY; LETTER; MEDICAL RESEARCH; METHODOLOGY; NAUSEA; NEUROPATHIC PAIN; PAIN; PLACEBO EFFECT; PRIORITY JOURNAL; SIDE EFFECT; THORAX PAIN; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ANALGESICS; CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; FIBROMYALGIA; GAMMA-AMINOBUTYRIC ACID; HUMANS; LONGITUDINAL STUDIES; OUTCOME ASSESSMENT (HEALTH CARE); PLACEBO EFFECT; THIOPHENES; TREATMENT OUTCOME;

EID: 53249154266     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2008.07.026     Document Type: Letter

References (10)

1. Staud R., and Price D.D. Long-term trials of pregabalin and duloxetine for fibromyalgia symptoms: how study designs can affect placebo factors. Pain 136 (2008) 232-234
2. McQuay H.J., Derry S., Moore R.A., Poulain P., and Legout V. Enriched enrolment with randomised withdrawal (EERW): time for a new look at clinical trial design in chronic pain. Pain 135 (2008) 217-220
3. Crofford L.J., Mease P.J., Simpson S.L., Young Jr. J.P., Martin S.A., Haig G.M., et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain 136 (2008) 419-431
4. Russell I.J., Mease P.J., Smith T.R., Kajdasz D.K., Wohlreich M.M., Detke M.J., et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 136 (2008) 432-444
5. Straube S., Derry S., McQuay H.J., and Moore R.A. Enriched enrolment: definition, and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. Br J Clin Pharm 16 May [Epub ahead of print] (2008)
6. Kaptchuk T.J., Stason W.B., Davis R.B., Legedza A.R., Schnyer R.N., Kerr C.E., et al. Sham device v inert pill: randomised controlled trial of two placebo treatments. BMJ 332 (2006) 391-397
7. Rief W., Avorn J., and Barsky A.J. Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effects. Arch Intern Med 166 (2006) 155-160
8. Meyer F.P., Tröger U., and Röhl F.W. Adverse nondrug reactions: an update. Clin Pharm Ther 60 (1996) 347-352
9. Demyttenaere K., Albert A., Mesters P., Dewé W., De Bruyckere K., and Sangeleer M. What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors?. J Clin Psychiatry 66 (2005) 859-863
10. Meyer F.P., Tröger U., and Röhl F.W. Reliability of symptom reports by healthy volunteers treated with placebo over several time periods. Arzneimittelforschung 50 (2000) 768-771